| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | pluripotin | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.014 | 0.9 |
| mRNA | ouabain | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.9 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | HBX-41108 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |